[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100353124":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":29,"responsibleParty":178,"collaborators":180,"id":184,"slug":185,"hasResults":186,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":10,"eligibilityCriteria":190,"healthyVolunteers":186,"sex":191,"minAge":192,"maxAge":10,"enrollmentInfo":193,"targetDuration":10,"studyType":196,"phases":10,"briefSummary":197,"conditions":198,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":209},{"fullName":5,"class":6},"Allarity Therapeutics","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Ovarian cancer patients",null,"with formalin-fixed paraffin-embedded (FFPE) tumor tissue available",[13],"Device: Drug Response Predictor® (DRP)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DEVICE","Drug Response Predictor® (DRP)","A DRP is an assay that based on samples from a tumor can predict whether the tumor will respond to a specific drug or not.",[9],[21,26],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"US: Kathleen Moore","CONTACT","+1 405-271-8707","KathleenMoore@ouhealth.com",{"name":27,"role":23,"phone":10,"phoneExt":10,"email":28},"Europe: Rebecca Kristeleit","Rebecca.Kristeleit@gstt.nhs.uk",[30,47,65,81,97,114,130,147,165],{"facility":31,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Moffitt Cancer Center","RECRUITING","Tampa","Florida","33612","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-82.45843,27.94752,{"lat":42,"lon":41},[45],{"name":46,"role":23,"phone":10,"phoneExt":10,"email":10},"Merry Markham, MD",{"facility":48,"status":32,"city":49,"state":50,"zip":51,"country":36,"countryCode":37,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"Emory Winship Cancer Institute","Atlanta","Georgia","30322",{"type":39,"coordinates":53},[54,55],-84.38798,33.749,{"lat":55,"lon":54},[58,62],{"name":59,"role":23,"phone":60,"phoneExt":10,"email":61},"Nilaab Meer","494-778-1900","nilaab.meer@emory.edu",{"name":63,"role":64,"phone":10,"phoneExt":10,"email":10},"Jennifer Scalici, MD","PRINCIPAL_INVESTIGATOR",{"facility":66,"status":32,"city":67,"state":68,"zip":69,"country":36,"countryCode":37,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"University of New Mexico Comprehensive Cancer","Albuquerque","New Mexico","87131",{"type":39,"coordinates":71},[72,73],-106.65114,35.08449,{"lat":73,"lon":72},[76,79],{"name":77,"role":23,"phone":10,"phoneExt":10,"email":78},"Natalie Everett","nseverett@salud.unm.edu",{"name":80,"role":64,"phone":10,"phoneExt":10,"email":10},"Amaranta Craig, MD",{"facility":82,"status":32,"city":83,"state":83,"zip":84,"country":36,"countryCode":37,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"The Blavatnik Family-Chelsea Medical Center at Mount Sinai","New York","10011",{"type":39,"coordinates":86},[87,88],-74.00597,40.71427,{"lat":88,"lon":87},[91,95],{"name":92,"role":23,"phone":93,"phoneExt":10,"email":94},"Neha Kumarley","212-824-7859","neha.kumarley@mssm.edu",{"name":96,"role":64,"phone":10,"phoneExt":10,"email":10},"Stephanie Blank, MD",{"facility":98,"status":32,"city":99,"state":100,"zip":101,"country":36,"countryCode":37,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"OU Health Stephenson Cancer Center","Oklahoma City","Oklahoma","73104",{"type":39,"coordinates":103},[104,105],-97.51643,35.46756,{"lat":105,"lon":104},[108,112],{"name":109,"role":23,"phone":110,"phoneExt":10,"email":111},"Christine Pappaterra, RN","405-271-8707","Christine-Pappaterra@ouhsc.edu",{"name":113,"role":64,"phone":10,"phoneExt":10,"email":10},"Jacqueline Bohn,, MD",{"facility":115,"status":32,"city":116,"state":117,"zip":118,"country":36,"countryCode":37,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"University Medical Center Cancer Center","Lubbock","Texas","79415",{"type":39,"coordinates":120},[121,122],-101.85517,33.57786,{"lat":122,"lon":121},[125,128],{"name":126,"role":23,"phone":10,"phoneExt":10,"email":127},"Mariana Fiori","Mariana.Fiori@ttuhsc.edu",{"name":129,"role":64,"phone":10,"phoneExt":10,"email":10},"Mark Reedy, MD",{"facility":131,"status":32,"city":132,"state":133,"zip":134,"country":36,"countryCode":37,"cosmosGeoPoint":135,"geoPoint":139,"contacts":140},"Swedish Center for Research and Innovation","Seattle","Washington","98122",{"type":39,"coordinates":136},[137,138],-122.33207,47.60621,{"lat":138,"lon":137},[141,145],{"name":142,"role":23,"phone":143,"phoneExt":10,"email":144},"Karina Sills","206-386-2227","karina.sills@swedish.org",{"name":146,"role":64,"phone":10,"phoneExt":10,"email":10},"Fernanda Baptista Musa, MD",{"facility":148,"status":32,"city":149,"state":150,"zip":151,"country":152,"countryCode":153,"cosmosGeoPoint":154,"geoPoint":158,"contacts":159},"Beatson West of Scotland Cancer Centre","Glasgow","Scotland","G12 0YN","United Kingdom","UK",{"type":39,"coordinates":155},[156,157],-4.25763,55.86515,{"lat":157,"lon":156},[160,163],{"name":161,"role":23,"phone":10,"phoneExt":10,"email":162},"Lauren Mcnamara","lauren.mcnamara@ggc.scot.nhs.uk",{"name":164,"role":64,"phone":10,"phoneExt":10,"email":10},"Ros Glasspool, MD",{"facility":166,"status":32,"city":167,"state":10,"zip":10,"country":152,"countryCode":153,"cosmosGeoPoint":168,"geoPoint":172,"contacts":173},"Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital","London",{"type":39,"coordinates":169},[170,171],-0.12574,51.50853,{"lat":171,"lon":170},[174,176],{"name":175,"role":23,"phone":10,"phoneExt":10,"email":10},"Rebecca Kristeleit, MD",{"name":177,"role":23,"phone":10,"phoneExt":10,"email":10},"Samantha Barrett",{"type":179,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[181],{"name":182,"class":183},"Amarex Clinical Research","OTHER","100353124","clinical-pre-screening-protocol-for-ovarian-cancer-100353124",false,"NCT03877796","Clinical Pre-screening Protocol for Ovarian Cancer","Development of Drug Response Predictor (DRP) to Test Sensitivity to Investigational Anti-Cancer Drugs in Patients With Advanced Ovarian Cancer","Inclusion Criteria:\n\n* Patients with histological confirmed epithelia ovarian cancer\n* Patients must have platinum-resistant disease, defined as progression within 6 months after the last dose of platinum-based chemotherapy, or are platinum ineligible.\n* Patients have received no more than one prior line of therapy in the platinum resistant or platinum ineligible setting\n* FFPE tumor tissue available\n\nExclusion Criteria:\n\n* Patients who have platinum-refractory disease, defined as progression during the last platinum-based chemotherapy.\n* Other malignancy with exception of any stage I and II cancer that is deemed cured by the Investigator","FEMALE","18 Years",{"count":194,"type":195},60,"ESTIMATED","OBSERVATIONAL","The patient's local archival tumor tissue (FFPE) from original tumor, or from the metastatic tissue, will be collected to potentially identify if they - at a later stage of their disease - will be likely to benefit from treatment with any of the investigational cancer drugs available to Allarity Therapeutics. Data from this study can further be used to explore in a retrospective fashion, sensitivity to other chemotherapeutic drugs previously used in the treatment of their ovarian cancer, to investigate whether or not the DRP® method can predict and confirm the obtained sensitivity to the prior given drugs as well as prospective analyses guiding the Investigators on future treatments.",[199],"Ovarian Cancer","2026-07-29",{"date":202,"type":203},"2026-07-30","ACTUAL",{"date":205,"type":203},"2019-04-11",{"date":207,"type":195},"2027-12",{"name":5,"class":6},9]